Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for ruxolitinib for vitiligo

  1. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1140)

    Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.

    Technology appraisal guidance
    Published
    17 March 2026
    View recommendations

    Sections for TA1140

  2. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1140).

    Withdrawn guidance

  3. First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people

    For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo

    News
    Last updated
    24 February 2026